ArticleBMJ open quality2026
Study on the effectiveness and accessibility of a CDR-based VTE quality control platform in county-level hospitals.
Article in BMJ open quality, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To enhance venous thromboembolism (VTE) prevention and management in county-level hospitals, we developed a VTE quality control platform leveraging clinical databases and Clinician Workstations. The platform is characterised by simplified construction, cost-effectiveness and a user-friendly interface enabling precise real-time monitoring of VTE prevention measures in hospitalised patients. Comparative analysis of pre-implementation and post implementation data revealed significant improvements in key metrics: VTE bleeding risk assessment rate (1.33% vs 7.43%, p<0.001), basic prevention compliance (20.87% vs 50.38%, p<0.001), mechanical prevention utilisation (24.60% vs 27.37%, p=0.002) and appropriate prevention rate (11.67% vs 53.11%, p<0.001). The platform effectively optimised VTE prevention practices, demonstrating ease of deployment, affordability and operational efficiency-making it a scalable and practical solution for county-level hospitals in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.